{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T11:05:47Z","timestamp":1789297547941,"version":"build-2803163510"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T00:00:00Z","timestamp":1789171200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T00:00:00Z","timestamp":1789171200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100031765","name":"Central Surgical Association","doi-asserted-by":"publisher","award":["Turcotte Award"],"award-info":[{"award-number":["Turcotte Award"]}],"id":[{"id":"10.13039\/100031765","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Institute of Health; National Cancer Institute","award":["K12 CA133250 (NIH\/NCI)"],"award-info":[{"award-number":["K12 CA133250 (NIH\/NCI)"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pancreatic ductal adenocarcinoma (PDAC) remains a highly lethal malignancy with limited long-term survival despite advances in surgery and systemic therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients<\/jats:title>\n                    <jats:p>The population of interest comprises patients with PDAC characterized by targetable molecular alterations and biologically distinct transcriptomic subtypes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a narrative review of landmark and contemporary clinical trials, translational studies, and emerging molecular-classification platforms relevant to precision oncology in PDAC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Growing understanding of PDAC molecular biology has identified putative genetic mutations, including homologous recombination repair deficiency, mismatch repair deficiency, and mutated KRAS, enabling the development of targeted therapies and precision treatment strategies. Concurrently, transcriptomic profiling has revealed biologically distinct molecular subtypes associated with differences in prognosis and therapeutic response. Emerging tools such as molecular classifiers, deep learning models, and multiomic platforms may further refine patient selection and treatment personalization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This review highlights contemporary efforts of novel targeted therapies, ongoing advances in molecular subtyping, and the evolving role of precision oncology in improving outcomes for patients with PDAC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1245\/s10434-026-20366-0","type":"journal-article","created":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T18:29:29Z","timestamp":1789237769000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Landmark Series: Mutation-Based Therapy of Pancreatic Cancer"],"prefix":"10.1245","author":[{"given":"McKenzie L.","family":"Schaefer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex B.","family":"Blair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,12]]},"reference":[{"issue":"5","key":"20366_CR1","doi-asserted-by":"publisher","first-page":"318","DOI":"10.3322\/caac.21190","volume":"63","author":"CL Wolfgang","year":"2013","unstructured":"Wolfgang CL, Herman JM, Laheru DA, et al. Recent progress in pancreatic cancer. CA Cancer J Clin. 2013;63(5):318\u201348. https:\/\/doi.org\/10.3322\/caac.21190.","journal-title":"CA Cancer J Clin."},{"issue":"1","key":"20366_CR2","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12\u201349. https:\/\/doi.org\/10.3322\/caac.21820.","journal-title":"CA Cancer J Clin."},{"issue":"25","key":"20366_CR3","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","volume":"379","author":"T Conroy","year":"2018","unstructured":"Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379(25):2395\u2013406. https:\/\/doi.org\/10.1056\/NEJMoa1809775.","journal-title":"N Engl J Med."},{"key":"20366_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2019.04.007","author":"VP Groot","year":"2019","unstructured":"Groot VP, Blair AB, Gemenetzis G, et al. Recurrence after neoadjuvant therapy and resection of borderline resectable and locally advanced pancreatic cancer. Eur J Surg Oncol. 2019. https:\/\/doi.org\/10.1016\/j.ejso.2019.04.007.","journal-title":"Eur J Surg Oncol"},{"key":"20366_CR5","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000002234","author":"VP Groot","year":"2017","unstructured":"Groot VP, Rezaee N, Wu W, et al. Patterns, timing, and predictors of recurrence following pancreatectomy for pancreatic ductal adenocarcinoma. Ann Surg. 2017. https:\/\/doi.org\/10.1097\/SLA.0000000000002234.","journal-title":"Ann Surg."},{"issue":"13","key":"20366_CR6","doi-asserted-by":"publisher","first-page":"3239","DOI":"10.1158\/1078-0432.CCR-20-0418","volume":"26","author":"W Park","year":"2020","unstructured":"Park W, Chen J, Chou JF, et al. Genomic methods identify homologous recombination deficiency in pancreas adenocarcinoma and optimize treatment selection. Clin Cancer Res. 2020;26(13):3239\u201347. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-0418.","journal-title":"Clin Cancer Res."},{"issue":"2","key":"20366_CR7","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/s0092-8674(02)00615-3","volume":"108","author":"AR Venkitaraman","year":"2002","unstructured":"Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell. 2002;108(2):171\u201382. https:\/\/doi.org\/10.1016\/s0092-8674(02)00615-3.","journal-title":"Cell."},{"key":"20366_CR8","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1101\/sqb.2005.70.012","volume":"70","author":"AN Tutt","year":"2005","unstructured":"Tutt AN, Lord CJ, McCabe N, et al. Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer. Cold Spring Harb Symp Quant Biol. 2005;70:139\u201348. https:\/\/doi.org\/10.1101\/sqb.2005.70.012.","journal-title":"Cold Spring Harb Symp Quant Biol."},{"issue":"7035","key":"20366_CR9","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nature03445","volume":"434","author":"H Farmer","year":"2005","unstructured":"Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434(7035):917\u201321. https:\/\/doi.org\/10.1038\/nature03445.","journal-title":"Nature."},{"issue":"4","key":"20366_CR10","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1903387","volume":"381","author":"T Golan","year":"2019","unstructured":"Golan T, Hammel P, Reni M, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med. 2019;381(4):317\u201327. https:\/\/doi.org\/10.1056\/NEJMoa1903387.","journal-title":"N Engl J Med."},{"issue":"34","key":"20366_CR11","doi-asserted-by":"publisher","first-page":"3929","DOI":"10.1200\/JCO.21.01604","volume":"40","author":"HL Kindler","year":"2022","unstructured":"Kindler HL, Hammel P, Reni M, et al. Overall survival results from the POLO Trial: a phase III study of active maintenance olaparib versus placebo for germline BRCA-mutated metastatic pancreatic cancer. J Clin Oncol. 2022;40(34):3929\u201339. https:\/\/doi.org\/10.1200\/JCO.21.01604.","journal-title":"J Clin Oncol."},{"issue":"22","key":"20366_CR12","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1200\/JCO.21.00003","volume":"39","author":"KA Reiss","year":"2021","unstructured":"Reiss KA, Mick R, O\u2019Hara MH, et al. Phase II study of maintenance rucaparib in patients with platinum-sensitive advanced pancreatic cancer and a pathogenic germline or somatic variant in BRCA1, BRCA2, or PALB2. J Clin Oncol. 2021;39(22):2497\u2013505. https:\/\/doi.org\/10.1200\/JCO.21.00003.","journal-title":"J Clin Oncol."},{"issue":"3","key":"20366_CR13","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1200\/JCO.2024.42.3_suppl.661","volume":"42","author":"KA Reiss","year":"2024","unstructured":"Reiss KA, O\u2019Hara MH, Teitelbaum UR, et al. A phase II study of maintenance rucaparib in patients with platinum sensitive, advanced pancreatic cancer and a pathogenic germline or somatic variant in BRCA1, BRCA2 or PALB2: a four year survival update. J Clin Oncol. 2024;42(3):661\u2013661. https:\/\/doi.org\/10.1200\/JCO.2024.42.3_suppl.661.","journal-title":"J Clin Oncol."},{"key":"20366_CR14","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2026.0870","author":"KA Reiss","year":"2026","unstructured":"Reiss KA, Xia M, Akamandisa M, et al. Long-term outcomes of patients with BRCA+ or PALB2+ pancreatic cancer treated with maintenance rucaparib: a secondary analysis of a nonrandomized clinical trial. JAMA Oncology. 2026. https:\/\/doi.org\/10.1001\/jamaoncol.2026.0870.","journal-title":"JAMA Oncology."},{"issue":"8","key":"20366_CR15","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/S1470-2045(22)00369-2","volume":"23","author":"KA Reiss","year":"2022","unstructured":"Reiss KA, Mick R, Teitelbaum U, et al. Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b\/2 trial. Lancet Oncol. 2022;23(8):1009\u201320. https:\/\/doi.org\/10.1016\/S1470-2045(22)00369-2.","journal-title":"Lancet Oncol."},{"key":"20366_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-026-04299-5","author":"W Park","year":"2026","unstructured":"Park W, O\u2019Connor CA, Chou JF, et al. Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial. Nat Med. 2026. https:\/\/doi.org\/10.1038\/s41591-026-04299-5.","journal-title":"Nat Med."},{"issue":"25","key":"20366_CR17","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","volume":"384","author":"ANJ Tutt","year":"2021","unstructured":"Tutt ANJ, Garber JE, Kaufman B, et al. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med. 2021;384(25):2394\u2013405. https:\/\/doi.org\/10.1056\/NEJMoa2105215.","journal-title":"N Engl J Med."},{"issue":"12","key":"20366_CR18","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1016\/j.annonc.2022.09.159","volume":"33","author":"CE Geyer Jr","year":"2022","unstructured":"Geyer CE Jr, Garber JE, Gelber RD, et al. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1\/2 and high-risk, early breast cancer. Ann Oncol. 2022;33(12):1250\u201368. https:\/\/doi.org\/10.1016\/j.annonc.2022.09.159.","journal-title":"Ann Oncol."},{"issue":"9","key":"20366_CR19","doi-asserted-by":"publisher","first-page":"5375","DOI":"10.1245\/s10434-022-11917-2","volume":"29","author":"ME Teke","year":"2022","unstructured":"Teke ME, Saif A, Ryan CE, Lux SC, Hernandez JM, Reiss KA. A randomized study of olaparib or placebo in patients with surgically removed pancreatic cancer who have a BRCA1, BRCA2 or PALB2 mutation (the APOLLO trial). Ann Surg Oncol. 2022;29(9):5375\u20136. https:\/\/doi.org\/10.1245\/s10434-022-11917-2.","journal-title":"Ann Surg Oncol."},{"issue":"3","key":"20366_CR20","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/s41416-019-0582-7","volume":"122","author":"MM Wattenberg","year":"2020","unstructured":"Wattenberg MM, Asch D, Yu S, et al. Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation. Br J Cancer. 2020;122(3):333\u20139. https:\/\/doi.org\/10.1038\/s41416-019-0582-7.","journal-title":"Br J Cancer."},{"key":"20366_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamcollsurg.2017.12.021","author":"AB Blair","year":"2018","unstructured":"Blair AB, Groot VP, Gemenetzis G, et al. BRCA1\/BRCA2 germline mutation carriers and sporadic pancreatic ductal adenocarcinoma. J Am Coll Surg. 2018. https:\/\/doi.org\/10.1016\/j.jamcollsurg.2017.12.021.","journal-title":"J Am Coll Surg."},{"key":"20366_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.18.00271","volume":"3","author":"S Yu","year":"2019","unstructured":"Yu S, Agarwal P, Mamtani R, et al. Retrospective survival analysis of patients with resected pancreatic ductal adenocarcinoma and a germline BRCA or PALB2 mutation. JCO Precis Oncol. 2019;3:1\u201311. https:\/\/doi.org\/10.1200\/PO.18.00271.","journal-title":"JCO Precis Oncol."},{"issue":"1","key":"20366_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JCO.19.02105","volume":"38","author":"A Marabelle","year":"2020","unstructured":"Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 Study. J Clin Oncol. 2020;38(1):1\u201310. https:\/\/doi.org\/10.1200\/JCO.19.02105.","journal-title":"J Clin Oncol."},{"key":"20366_CR24","doi-asserted-by":"publisher","DOI":"10.1200\/PO.22.00706","volume":"7","author":"T Coston","year":"2023","unstructured":"Coston T, Desai A, Babiker H, et al. Efficacy of immune checkpoint inhibition and cytotoxic chemotherapy in mismatch repair-deficient and microsatellite instability-high pancreatic cancer: mayo clinic experience. JCO Precis Oncol. 2023;7:e2200706. https:\/\/doi.org\/10.1200\/PO.22.00706.","journal-title":"JCO Precis Oncol."},{"key":"20366_CR25","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ejca.2023.04.012","volume":"188","author":"J Taieb","year":"2023","unstructured":"Taieb J, Sayah L, Heinrich K, et al. Efficacy of immune checkpoint inhibitors in microsatellite unstable\/mismatch repair-deficient advanced pancreatic adenocarcinoma: an AGEO European Cohort. Eur J Cancer. 2023;188:90\u20137. https:\/\/doi.org\/10.1016\/j.ejca.2023.04.012.","journal-title":"Eur J Cancer."},{"issue":"7424","key":"20366_CR26","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nature11547","volume":"491","author":"AV Biankin","year":"2012","unstructured":"Biankin AV, Waddell N, Kassahn KS, et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature. 2012;491(7424):399\u2013405. https:\/\/doi.org\/10.1038\/nature11547.","journal-title":"Nature."},{"key":"20366_CR27","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a031435","author":"AM Waters","year":"2018","unstructured":"Waters AM, Der CJ. KRAS: the critical driver and therapeutic target for pancreatic cancer. Cold Spring Harb Perspect Med. 2018. https:\/\/doi.org\/10.1101\/cshperspect.a031435.","journal-title":"Cold Spring Harb Perspect Med."},{"issue":"1","key":"20366_CR28","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/s41392-021-00780-4","volume":"6","author":"L Huang","year":"2021","unstructured":"Huang L, Guo Z, Wang F, Fu L. KRAS mutation: from undruggable to druggable in cancer. Signal Transduct Target Ther. 2021;6(1):386. https:\/\/doi.org\/10.1038\/s41392-021-00780-4.","journal-title":"Signal Transduct Target Ther."},{"issue":"16","key":"20366_CR29","doi-asserted-by":"publisher","first-page":"4848","DOI":"10.1073\/pnas.79.16.4848","volume":"79","author":"EH Chang","year":"1982","unstructured":"Chang EH, Gonda MA, Ellis RW, Scolnick EM, Lowy DR. Human genome contains four genes homologous to transforming genes of Harvey and Kirsten murine sarcoma viruses. Proc Natl Acad Sci U S A. 1982;79(16):4848\u201352. https:\/\/doi.org\/10.1073\/pnas.79.16.4848.","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"1","key":"20366_CR30","doi-asserted-by":"publisher","first-page":"3687","DOI":"10.1038\/s41598-017-03973-6","volume":"7","author":"MP Muller","year":"2017","unstructured":"Muller MP, Jeganathan S, Heidrich A, Campos J, Goody RS. Nucleotide based covalent inhibitors of KRas can only be efficient in vivo if they bind reversibly with GTP-like affinity. Sci Rep. 2017;7(1):3687. https:\/\/doi.org\/10.1038\/s41598-017-03973-6.","journal-title":"Sci Rep."},{"issue":"8","key":"20366_CR31","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/nrc.2017.36","volume":"17","author":"CV Dang","year":"2017","unstructured":"Dang CV, Reddy EP, Shokat KM, Soucek L. Drugging the \u2018undruggable\u2019 cancer targets. Nat Rev Cancer. 2017;17(8):502\u20138. https:\/\/doi.org\/10.1038\/nrc.2017.36.","journal-title":"Nat Rev Cancer."},{"issue":"3","key":"20366_CR32","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.cell.2018.01.006","volume":"172","author":"MR Janes","year":"2018","unstructured":"Janes MR, Zhang J, Li LS, et al. Targeting KRAS mutant cancers with a covalent G12C-specific inhibitor. Cell. 2018;172(3):578\u201389. https:\/\/doi.org\/10.1016\/j.cell.2018.01.006.","journal-title":"Cell."},{"issue":"7781","key":"20366_CR33","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","volume":"575","author":"J Canon","year":"2019","unstructured":"Canon J, Rex K, Saiki AY, et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature. 2019;575(7781):217\u201323. https:\/\/doi.org\/10.1038\/s41586-019-1694-1.","journal-title":"Nature."},{"issue":"25","key":"20366_CR34","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","volume":"384","author":"F Skoulidis","year":"2021","unstructured":"Skoulidis F, Li BT, Dy GK, et al. Sotorasib for lung cancers with KRAS p.G12C mutation. N Engl J Med. 2021;384(25):2371\u201381. https:\/\/doi.org\/10.1056\/NEJMoa2103695.","journal-title":"N Engl J Med."},{"issue":"2","key":"20366_CR35","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1056\/NEJMoa2204619","volume":"387","author":"PA Janne","year":"2022","unstructured":"Janne PA, Riely GJ, Gadgeel SM, et al. Adagrasib in non-small-cell lung cancer harboring a KRAS(G12C) mutation. N Engl J Med. 2022;387(2):120\u201331. https:\/\/doi.org\/10.1056\/NEJMoa2204619.","journal-title":"N Engl J Med."},{"issue":"1","key":"20366_CR36","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa2208470","volume":"388","author":"JH Strickler","year":"2023","unstructured":"Strickler JH, Satake H, George TJ, et al. Sotorasib in KRAS p.G12C-mutated advanced pancreatic cancer. N Engl J Med. 2023;388(1):33\u201343. https:\/\/doi.org\/10.1056\/NEJMoa2208470.","journal-title":"N Engl J Med."},{"issue":"25","key":"20366_CR37","doi-asserted-by":"publisher","first-page":"4097","DOI":"10.1200\/JCO.23.00434","volume":"41","author":"TS Bekaii-Saab","year":"2023","unstructured":"Bekaii-Saab TS, Yaeger R, Spira AI, et al. Adagrasib in advanced solid tumors harboring a KRAS(G12C) mutation. J Clin Oncol. 2023;41(25):4097\u2013106. https:\/\/doi.org\/10.1200\/JCO.23.00434.","journal-title":"J Clin Oncol."},{"issue":"4","key":"20366_CR38","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1200\/JCO.2025.43.4_suppl.724","volume":"43","author":"AI Spira","year":"2025","unstructured":"Spira AI, Papadopoulos KP, Kim DW, et al. Preliminary safety, antitumor activity, and circulating tumor DNA (ctDNA) changes with RMC-9805, an oral, RAS(ON) G12D-selective tri-complex inhibitor in patients with KRAS G12D pancreatic ductal adenocarcinoma (PDAC) from a phase 1 study in advanced solid tumors. J Clin Oncol. 2025;43(4):724\u2013724. https:\/\/doi.org\/10.1200\/JCO.2025.43.4_suppl.724.","journal-title":"J Clin Oncol."},{"issue":"14","key":"20366_CR39","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1056\/NEJMoa2600752","volume":"394","author":"W Park","year":"2026","unstructured":"Park W, Kasi A, Spira AI, et al. Setidegrasib in advanced non\u2013small-cell lung cancer and pancreatic cancer. N Engl J Med. 2026;394(14):1409\u201320. https:\/\/doi.org\/10.1056\/NEJMoa2600752.","journal-title":"N Engl J Med."},{"issue":"5","key":"20366_CR40","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1158\/2159-8290.Cd-25-1346","volume":"16","author":"L Xie","year":"2026","unstructured":"Xie L, Xu C, Si H, et al. Preclinical characterization and clinical activity of RNK08954, a highly selective and orally bioavailable KRASG12D inhibitor. Cancer Discov. 2026;16(5):895\u2013910. https:\/\/doi.org\/10.1158\/2159-8290.Cd-25-1346.","journal-title":"Cancer Discov."},{"issue":"9","key":"20366_CR41","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1016\/j.ccell.2024.08.002","volume":"42","author":"CA McIntyre","year":"2024","unstructured":"McIntyre CA, Grimont A, Park J, et al. Distinct clinical outcomes and biological features of specific KRAS mutants in human pancreatic cancer. Cancer Cell. 2024;42(9):1614\u201329. https:\/\/doi.org\/10.1016\/j.ccell.2024.08.002.","journal-title":"Cancer Cell."},{"key":"20366_CR42","doi-asserted-by":"crossref","unstructured":"Kamgar M, Hobbs GA, Davidson R, et al. MEK inhibitor therapy in pancreatic ductal adenocarcinoma with KRAS G12R mutation. Cell Rep Med. 2024;Sneak Peek: Available at SSRN: https:\/\/ssrn.com\/abstract=4989933","DOI":"10.2139\/ssrn.4989933"},{"issue":"6659","key":"20366_CR43","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1126\/science.adg9652","volume":"381","author":"CJ Schulze","year":"2023","unstructured":"Schulze CJ, Seamon KJ, Zhao Y, et al. Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS. Science. 2023;381(6659):794\u20139. https:\/\/doi.org\/10.1126\/science.adg9652.","journal-title":"Science."},{"issue":"6","key":"20366_CR44","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1158\/2159-8290.CD-24-0027","volume":"14","author":"J Jiang","year":"2024","unstructured":"Jiang J, Jiang L, Maldonato BJ, et al. Translational and therapeutic evaluation of RAS-GTP inhibition by RMC-6236 in RAS-driven cancers. Cancer Discov. 2024;14(6):994\u20131017. https:\/\/doi.org\/10.1158\/2159-8290.CD-24-0027.","journal-title":"Cancer Discov."},{"issue":"18","key":"20366_CR45","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1056\/NEJMoa2505783","volume":"394","author":"BM Wolpin","year":"2026","unstructured":"Wolpin BM, Park W, Garrido-Laguna I, et al. Daraxonrasib in previously treated advanced RAS-mutated pancreatic cancer. New Engl J Med. 2026;394(18):1790\u2013802. https:\/\/doi.org\/10.1056\/NEJMoa2505783.","journal-title":"New Engl J Med."},{"issue":"16","key":"20366_CR46","doi-asserted-by":"publisher","first-page":"TPS4230","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS4230","volume":"43","author":"BM Wolpin","year":"2025","unstructured":"Wolpin BM, Wainberg ZA, Garrido-Laguna I, et al. Trial in progress: RASolute 302: a phase 3, multicenter, global, open-label, randomized study of daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor, versus standard of care chemotherapy in patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC). J Clin Oncol. 2025;43(16):TPS4230\u2013TPS4230. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.TPS4230.","journal-title":"J Clin Oncol."},{"issue":"1","key":"20366_CR47","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1038\/s41467-026-68324-4","volume":"17","author":"AL Huff","year":"2026","unstructured":"Huff AL, Haldar SD, Girgis AA, et al. Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial. Nat Commun. 2026;17(1):1538. https:\/\/doi.org\/10.1038\/s41467-026-68324-4.","journal-title":"Nat Commun."},{"issue":"7493","key":"20366_CR48","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/nature12978","volume":"507","author":"H Liu","year":"2014","unstructured":"Liu H, Moynihan KD, Zheng Y, et al. Structure-based programming of lymph-node targeting in molecular vaccines. Nature. 2014;507(7493):519\u201322. https:\/\/doi.org\/10.1038\/nature12978.","journal-title":"Nature."},{"issue":"6449","key":"20366_CR49","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1126\/science.aav8692","volume":"365","author":"L Ma","year":"2019","unstructured":"Ma L, Dichwalkar T, Chang JYH, et al. Enhanced CAR-T cell activity against solid tumors by vaccine boosting through the chimeric receptor. Science. 2019;365(6449):162\u20138. https:\/\/doi.org\/10.1126\/science.aav8692.","journal-title":"Science."},{"issue":"12","key":"20366_CR50","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1038\/nm.4200","volume":"22","author":"KD Moynihan","year":"2016","unstructured":"Moynihan KD, Opel CF, Szeto GL, et al. Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses. Nat Med. 2016;22(12):1402\u201310. https:\/\/doi.org\/10.1038\/nm.4200.","journal-title":"Nat Med."},{"key":"20366_CR51","doi-asserted-by":"crossref","unstructured":"O\u2019Reilly EM, Wainberg Z, Weekes CD, et al. AMPLIFY-201, a first in human safety and efficacy trial of adjuvant ELI-002 2P immunotherapy for patients with high-relapse risk G12D or G12R mutated pancreatic and colorectal cancer. J Clin Oncol. 2023;41(16)","DOI":"10.1200\/JCO.2023.41.16_suppl.2528"},{"key":"20366_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02760-3","author":"S Pant","year":"2024","unstructured":"Pant S, Wainberg ZA, Weekes CD, et al. Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial. Nat Med. 2024. https:\/\/doi.org\/10.1038\/s41591-023-02760-3.","journal-title":"Nat Med."},{"issue":"11","key":"20366_CR53","doi-asserted-by":"publisher","first-page":"3648","DOI":"10.1038\/s41591-025-03876-4","volume":"31","author":"ZA Wainberg","year":"2025","unstructured":"Wainberg ZA, Weekes CD, Furqan M, et al. Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results. Nat Med. 2025;31(11):3648\u201353. https:\/\/doi.org\/10.1038\/s41591-025-03876-4.","journal-title":"Nat Med."},{"issue":"7","key":"20366_CR54","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1158\/2326-6066.CIR-14-0027","volume":"2","author":"ER Lutz","year":"2014","unstructured":"Lutz ER, Wu AA, Bigelow E, et al. Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation. Cancer Immunol Res. 2014;2(7):616\u201331. https:\/\/doi.org\/10.1158\/2326-6066.CIR-14-0027.","journal-title":"Cancer Immunol Res."},{"issue":"4","key":"20366_CR55","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/nm.2344","volume":"17","author":"EA Collisson","year":"2011","unstructured":"Collisson EA, Sadanandam A, Olson P, et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med. 2011;17(4):500\u20133. https:\/\/doi.org\/10.1038\/nm.2344.","journal-title":"Nat Med."},{"issue":"10","key":"20366_CR56","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1038\/ng.3398","volume":"47","author":"RA Moffitt","year":"2015","unstructured":"Moffitt RA, Marayati R, Flate EL, et al. Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nat Genet. 2015;47(10):1168\u201378. https:\/\/doi.org\/10.1038\/ng.3398.","journal-title":"Nat Genet."},{"issue":"7540","key":"20366_CR57","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nature14169","volume":"518","author":"N Waddell","year":"2015","unstructured":"Waddell N, Pajic M, Patch AM, et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. 2015;518(7540):495\u2013501. https:\/\/doi.org\/10.1038\/nature14169.","journal-title":"Nature."},{"issue":"7592","key":"20366_CR58","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature16965","volume":"531","author":"P Bailey","year":"2016","unstructured":"Bailey P, Chang DK, Nones K, et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature. 2016;531(7592):47\u201352. https:\/\/doi.org\/10.1038\/nature16965.","journal-title":"Nature."},{"issue":"6","key":"20366_CR59","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1053\/j.gastro.2018.08.033","volume":"155","author":"F Puleo","year":"2018","unstructured":"Puleo F, Nicolle R, Blum Y, et al. Stratification of pancreatic ductal adenocarcinomas based on tumor and microenvironment features. Gastroenterology. 2018;155(6):1999-2013.e3. https:\/\/doi.org\/10.1053\/j.gastro.2018.08.033.","journal-title":"Gastroenterology."},{"issue":"21","key":"20366_CR60","doi-asserted-by":"publisher","first-page":"4932","DOI":"10.1158\/1078-0432.Ccr-24-1164","volume":"30","author":"H Singh","year":"2024","unstructured":"Singh H, Xiu J, Kapner KS, et al. Clinical and genomic features of classical and basal transcriptional subtypes in pancreatic cancer. Clin Cancer Res. 2024;30(21):4932\u201342. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-24-1164.","journal-title":"Clin Cancer Res."},{"issue":"4","key":"20366_CR61","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1136\/gutjnl-2020-321397","volume":"71","author":"B Kloesch","year":"2022","unstructured":"Kloesch B, Ionasz V, Paliwal S, et al. A GATA6-centred gene regulatory network involving HNFs and \u0394Np63 controls plasticity and immune escape in pancreatic cancer. Gut. 2022;71(4):766\u201377. https:\/\/doi.org\/10.1136\/gutjnl-2020-321397.","journal-title":"Gut."},{"key":"20366_CR62","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.70519","author":"MF Lansbergen","year":"2026","unstructured":"Lansbergen MF, Lanting VR, Manoukian P, et al. Transcriptome-based classification of resected pancreatic ductal adenocarcinoma enhances prognostic modelling accuracy of overall survival following adjuvant treatment. Int J Cancer. 2026. https:\/\/doi.org\/10.1002\/ijc.70519.","journal-title":"Int J Cancer."},{"issue":"18","key":"20366_CR63","doi-asserted-by":"publisher","first-page":"4901","DOI":"10.1158\/1078-0432.Ccr-19-3724","volume":"26","author":"GM O'Kane","year":"2020","unstructured":"O\u2019Kane GM, Gr\u00fcnwald BT, Jang GH, et al. GATA6 Expression distinguishes classical and basal-like subtypes in advanced pancreatic cancer. Clin Cancer Res. 2020;26(18):4901\u201310. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-19-3724.","journal-title":"Clin Cancer Res."},{"key":"20366_CR64","doi-asserted-by":"publisher","DOI":"10.1200\/po-25-00197","volume":"9","author":"S Wenric","year":"2025","unstructured":"Wenric S, Sangli C, Guittar J, et al. Real-world validation of the purity independent subtyping of tumors classifier for informing therapy selection in pancreatic ductal adenocarcinoma. JCO Precis Oncol. 2025;9:e2500197. https:\/\/doi.org\/10.1200\/po-25-00197.","journal-title":"JCO Precis Oncol."},{"issue":"31","key":"20366_CR65","doi-asserted-by":"publisher","first-page":"3355","DOI":"10.1200\/jco-25-00436","volume":"43","author":"JJ Knox","year":"2025","unstructured":"Knox JJ, O\u2019Kane G, King D, et al. PASS-01: randomized phase II trial of modified FOLFIRINOX versus gemcitabine\/nab-paclitaxel and molecular correlatives for previously untreated metastatic pancreatic cancer. J Clin Oncol. 2025;43(31):3355\u201368. https:\/\/doi.org\/10.1200\/jco-25-00436.","journal-title":"J Clin Oncol."},{"issue":"9","key":"20366_CR66","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1158\/1078-0432.CCR-15-0426","volume":"21","author":"LA Chantrill","year":"2015","unstructured":"Chantrill LA, Nagrial AM, Watson C, et al. Precision medicine for advanced pancreas cancer: the individualized molecular pancreatic cancer therapy (IMPaCT) trial. Clin Cancer Res. 2015;21(9):2029\u201337. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-0426.","journal-title":"Clin Cancer Res."},{"issue":"6","key":"20366_CR67","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1158\/1078-0432.CCR-17-2994","volume":"24","author":"KL Aung","year":"2018","unstructured":"Aung KL, Fischer SE, Denroche RE, et al. Genomics-driven precision medicine for advanced pancreatic cancer: early results from the COMPASS trial. Clin Cancer Res. 2018;24(6):1344\u201354. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-2994.","journal-title":"Clin Cancer Res."},{"issue":"1","key":"20366_CR68","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1158\/1078-0432.Ccr-19-1467","volume":"26","author":"NU Rashid","year":"2020","unstructured":"Rashid NU, Peng XL, Jin C, et al. Purity independent subtyping of tumors (PurIST), a clinically robust, single-sample classifier for tumor subtyping in pancreatic cancer. Clin Cancer Res. 2020;26(1):82\u201392. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-19-1467.","journal-title":"Clin Cancer Res."},{"issue":"11","key":"20366_CR69","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1016\/j.jmoldx.2024.07.002","volume":"26","author":"Y Li","year":"2024","unstructured":"Li Y, Merker JD, Kshatriya R, et al. Purity independent subtyping of tumors (PurIST) pancreatic cancer classifier: analytic validation of a 16-RNA expression signature distinguishing basal and classical subtypes. J Mol Diagn. 2024;26(11):962\u201370. https:\/\/doi.org\/10.1016\/j.jmoldx.2024.07.002.","journal-title":"J Mol Diagn."},{"issue":"1","key":"20366_CR70","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/jso.26756","volume":"125","author":"S Tsai","year":"2022","unstructured":"Tsai S, Evans DB. Lessons learned from investigator-initiated clinical trials for localized pancreatic cancer. J Surg Oncol. 2022;125(1):69\u201374. https:\/\/doi.org\/10.1002\/jso.26756.","journal-title":"J Surg Oncol."},{"issue":"6","key":"20366_CR71","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1002\/jso.26395","volume":"123","author":"EP Ward","year":"2021","unstructured":"Ward EP, Evans DB, Tsai S. Ten-year experience in optimizing neoadjuvant therapy for localized pancreatic cancer: medical college of Wisconsin perspective. J Surg Oncol. 2021;123(6):1405\u201313. https:\/\/doi.org\/10.1002\/jso.26395.","journal-title":"J Surg Oncol."},{"issue":"16","key":"20366_CR72","doi-asserted-by":"publisher","first-page":"4011","DOI":"10.1200\/JCO.2025.43.16_suppl.4011","volume":"43","author":"RA McLaughlin","year":"2025","unstructured":"McLaughlin RA, Jonker DJ, Karanicolas PJ, et al. NeoPancONE: GATA6 expression as a predictor of benefit to peri-operative modified FOLFIRINOX in resectable pancreatic adenocarcinoma (r-PDAC): a multicentre phase II study. J Clin Oncol. 2025;43(16):4011\u20134011. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.4011.","journal-title":"J Clin Oncol."},{"issue":"5","key":"20366_CR73","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1053\/j.gastro.2024.01.028","volume":"166","author":"B George","year":"2024","unstructured":"George B, Kudryashova O, Kravets A, et al. Transcriptomic-based microenvironment classification reveals precision medicine strategies for pancreatic ductal adenocarcinoma. Gastroenterology. 2024;166(5):859\u201371. https:\/\/doi.org\/10.1053\/j.gastro.2024.01.028.","journal-title":"Gastroenterology."},{"issue":"1","key":"20366_CR74","doi-asserted-by":"publisher","first-page":"3459","DOI":"10.1038\/s41467-023-39026-y","volume":"14","author":"C Saillard","year":"2023","unstructured":"Saillard C, Delecourt F, Schmauch B, et al. Pacpaint: a histology-based deep learning model uncovers the extensive intratumor molecular heterogeneity of pancreatic adenocarcinoma. Nat Commun. 2023;14(1):3459. https:\/\/doi.org\/10.1038\/s41467-023-39026-y.","journal-title":"Nat Commun."},{"issue":"2","key":"20366_CR75","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s43018-023-00697-7","volume":"5","author":"A Osipov","year":"2024","unstructured":"Osipov A, Nikolic O, Gertych A, et al. The molecular twin artificial-intelligence platform integrates multi-omic data to predict outcomes for pancreatic adenocarcinoma patients. Nat Cancer. 2024;5(2):299\u2013314. https:\/\/doi.org\/10.1038\/s43018-023-00697-7.","journal-title":"Nat Cancer."},{"issue":"5","key":"20366_CR76","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1001\/jamaoncol.2019.5963","volume":"6","author":"M Rainone","year":"2020","unstructured":"Rainone M, Singh I, Salo-Mullen EE, Stadler ZK, O\u2019Reilly EM. An emerging paradigm for germline testing in pancreatic ductal adenocarcinoma and immediate implications for clinical practice: a review. JAMA Oncol. 2020;6(5):764\u201371. https:\/\/doi.org\/10.1001\/jamaoncol.2019.5963.","journal-title":"JAMA Oncol."},{"issue":"1","key":"20366_CR77","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1136\/gutjnl-2020-320726","volume":"70","author":"C Luchini","year":"2021","unstructured":"Luchini C, Brosens LAA, Wood LD, et al. Comprehensive characterisation of pancreatic ductal adenocarcinoma with microsatellite instability: histology, molecular pathology and clinical implications. Gut. 2021;70(1):148\u201356. https:\/\/doi.org\/10.1136\/gutjnl-2020-320726.","journal-title":"Gut."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20366-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-20366-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20366-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T11:01:41Z","timestamp":1789297301000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-026-20366-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,12]]},"references-count":77,"alternative-id":["20366"],"URL":"https:\/\/doi.org\/10.1245\/s10434-026-20366-0","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,12]]},"assertion":[{"value":"18 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflicts of interest.","order":1,"name":"Ethics","label":"Disclosure","group":{"name":"EthicsHeading","label":"Ethics"}}]}}